Lucentis for pseudophakic CMO
Reviewed by Saruban Pasu

Pseudophakic cystoid macular oedema (CMO) develops angiographically in up to 20-30% after uneventful phacoemulsification. This study aimed to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic CMO after cataract surgery. Seven eyes were included in this retrospective observational study. All patients were refractory to previous treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids for at least three months. All patients received at least one intravitreal injection of 0.5mg ranibizumab. Patients received reinjections in case of recurrence of CMO (decrease of best corrected visual acuity (BCVA) >2 Snellen lines or as an increase in central retinal thickness (CRT) >100um on OCT). Both mean BCVA and mean CRT differed significantly pre and post injection. All patients presented resolution of macular oedema in about one month after intravitreal injection. One patient had recurrence of CMO three months after injection. No observable ocular side-effects were found in all patients. In line with other studies these results demonstrated that intravitreal ranibizumab is safe and effective in patients with pseudophakic cystoid macular oedema, providing a significant improvement in BCVA as well as a decrease in retinal thickness on OCT. These favourable and promising results support the need for further randomised case-control studies with large sample size to evaluate the safety and efficacy of intravitreal ranibizumab for this clinical entity. 

Intravitreal ranibizumab for the treatment of Irvine-Gass Syndrome.
Mitropoulos P, Chatziralli I, Peponis V, et al.
OCULAR IMMUNOLOGY AND INFLAMMATION
2015;23(3):225-31.